This inventor holds 1 USPTO granted patent. Top assignee: Visionrx.com, Inc.. Active years: 2000.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2000
Title: Scott Laird Whittenburg: Innovator in Visual Testing Technology
Introduction
Scott Laird Whittenburg is an accomplished inventor based in New Orleans, LA (US). He has made significant contributions to the field of visual testing, particularly in the area of glaucoma detection. His innovative approach utilizes color frequency doubling to enhance the accuracy of visual assessments.
Latest Patents
Whittenburg holds a patent for a novel psychophysical visual test designed for glaucoma testing. The patent, titled "Visual test utilizing color frequency doubling," proposes a unique method that leverages the frequency doubling phenomenon produced by isoluminent color visual stimuli. This method constructs a visual stimulus where alternating colors in a grating pattern serve as the sole basis for inducing the frequency doubling effect. The colors used are complementary pairs, such as blue and yellow, ensuring that they maintain the same luminance or intensity level.
Career Highlights
Scott Laird Whittenburg is currently associated with VisionRx.com, Inc., where he continues to develop and refine his innovative visual testing technologies. His work has the potential to significantly improve the early detection of glaucoma, a condition that can lead to irreversible vision loss if not diagnosed promptly.
Collaborations
Whittenburg collaborates with notable colleagues, including Stuart James McKinnon and Jeffrey L Stewart. Their combined expertise contributes to the advancement of visual testing methodologies and the development of new technologies in the field.
Conclusion
Scott Laird Whittenburg's contributions to visual testing technology exemplify the impact of innovation in healthcare. His patented methods offer promising advancements in the early detection of glaucoma, showcasing the importance of research and development in improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile